We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • Business

    Teladoc (NYSE:TDOC) Misses Q4 Sales Targets, Stock Drops 13.2%

    Jhon Posted on

    Breaking News

    Teladoc (NYSE:TDOC) Misses Q4 Sales Targets, Stock Drops 13.2%

    Published Feb 20, 2024 04:24PM ET Updated Feb 20, 2024 04:30PM ET

    Digital medical services platform Teladoc Health (NYSE:TDOC) fell short of analysts’ expectations in Q4 FY2023, with revenue up 3.6% year on year to $660.5 million. Next quarter’s revenue guidance of $637.5 million also underwhelmed, coming in 5.3% below analysts’ estimates. It made a GAAP loss of $0.17 per share, improving from its loss of $15.59 per share in the same quarter last year.

    Teladoc (TDOC) Q4 FY2023 Highlights:

    • Revenue: $660.5 million vs analyst estimates of $671.1 million (1.6% miss)
    • EPS: -$0.17 vs analyst estimates of -$0.24 (30.4% beat)
    • Revenue Guidance for Q1 2024 is $637.5 million at the midpoint, below analyst estimates of $672.9 million (adjusted EBITDA guidance missed for the period)
    • Management’s revenue guidance for the upcoming financial year 2024 is $2.69 billion at the midpoint, missing analyst estimates by 3.1% and implying 3.2% growth (vs 8.3% in FY2023) (adjusted EBITDA guidance ahead of expectations for the period)
    • Free Cash Flow of $93.58 million, similar to the previous quarter
    • Gross Margin (GAAP): 70.7%, in line with the same quarter last year
    • US Integrated Care Members: 89.6 million, up 6.3 million year on year
    • Market Capitalization: $3.48 billion

    “With approximately 90 million members and thousands of clients around the world, Teladoc Health continues to be the leader in whole person virtual care,” said Jason Gorevic, CEO of Teladoc Health.

    Founded to help people in rural areas get online medical consultations, Teladoc Health (NYSE:TDOC) is a telemedicine platform that facilitates remote doctor’s visits.

    Sales Growth

    Teladoc’s revenue growth over the last three years has been impressive, averaging 41% annually. This quarter, Teladoc reported rather lacklustre 3.6% year-on-year revenue growth, missing analysts’ expectations.

    Is now the time to buy Teladoc? Find out by reading the original article on StockStory.

    Tagged:

    LEAVE A RESPONSE

    Your email address will not be published. Required fields are marked *

    Jhon
    View all posts

    You Might Also Like